Nexelis, a provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has acquired AIT Bioscience, an integrated bioanalytical laboratory with LC-MS and immunoassay testing capabilities and operates a paperless FDA-inspected facility supported by state-of-the-art electronic systems.

Benoit Bouche, Nexelis President and Chief Executive Officer said, “This is our fourth acquisition since 2018 and we are excited for AIT Bioscience to join the Nexelis growth story. AIT Bioscience has a scientifically strong team and operates within a geography that we see as an attractive location for future growth. AIT Bioscience’s advanced testing capacity will help Nexelis further bolster its service offering in the bioanalytical segment and maintain competitive lead and turnaround times.”

Tim McGrath, Nexelis’ Chief Operating Officer who will oversee the Indianapolis operations, added, “I am happy and proud to have the responsibility to lead this new addition to Nexelis. This is an opportunity for me to work with experienced individuals, some of whom I have known for years. I am also excited to add large molecule mass spectrometry as a new service offering at Nexelis as this is a growing area where we now offer unique and specialized expertise.”

The company also recently acquired Belgium-based immunogenicity and immune-oncology specialist ImmunXperts and has initiated a number of strategic partnerships to support the development of COVID-19 and other vaccines and biologics with global pharmaceutical companies and institutions.